At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NERV Minerva Neurosciences
Market Closed 08-21 16:00:00 EDT
4.84
+0.05
+1.04%
盘后4.99
+0.15+3.10%
19:30 EDT
High5.07Low4.79Vol106.45K
Open4.79D1 Closing4.79Amplitude5.85%
Mkt Cap231.10MTradable Cap166.47MTotal Shares47.75M
T/O521.06KT/O Rate0.31%Tradable Shares34.39M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Minerva Neurosciences Files Form 3 for Chief Accounting Officer Anthony Aliquo
Reuters  ·  08-21 04:39
Minerva Neurosciences Files Form 3 for Chief Accounting Officer Anthony Aliquo
Minerva Neurosciences Raised to Buy from Hold by Jefferies
Dow Jones  ·  08-14
Minerva Neurosciences Raised to Buy from Hold by Jefferies
Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)
TIPRANKS  ·  08-14
Analysts Offer Insights on Healthcare Companies: Kyntra Bio (KYNB) and Minerva Neurosciences (NERV)
U.S. Research Roundup-Cisco, Fox Corp, Target
Reuters  ·  08-14
U.S. Research Roundup-Cisco, Fox Corp, Target
Minerva Neurosciences, Inc : Jefferies Raises to Buy from Hold; Raises Target Price to $10 from $7.5
THOMSON REUTERS  ·  08-14
Minerva Neurosciences, Inc : Jefferies Raises to Buy from Hold; Raises Target Price to $10 from $7.5
Minerva Neurosciences Elevates Aliquo to Accounting Leadership
TIPRANKS  ·  08-13
Minerva Neurosciences Elevates Aliquo to Accounting Leadership
Minerva Neurosciences Names Anthony Aliquo Chief Accounting Officer
Reuters  ·  08-13
Minerva Neurosciences Names Anthony Aliquo Chief Accounting Officer
Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate
Benzinga Earnings  ·  08-07
Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate
Minerva Neurosciences Returns to GAAP Profit in Q2 FY26 at $17.47 Million; GAAP Net Loss Widens to $107.94 Million in H1 FY26
Reuters  ·  08-07
Minerva Neurosciences Returns to GAAP Profit in Q2 FY26 at $17.47 Million; GAAP Net Loss Widens to $107.94 Million in H1 FY26
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
THOMSON REUTERS  ·  08-07
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia
Reuters  ·  06-05
Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
TIPRANKS  ·  06-05
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
Minerva Neurosciences shareholders approve charter amendments at annual meeting
Reuters  ·  06-05
Minerva Neurosciences shareholders approve charter amendments at annual meeting
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
THOMSON REUTERS  ·  06-02
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences - Topline Data From 12-Week Phase a Expected in Second Half of 2027
THOMSON REUTERS  ·  06-02
Minerva Neurosciences - Topline Data From 12-Week Phase a Expected in Second Half of 2027
Minerva Neurosciences forms scientific advisory board for roluperidone program
Reuters  ·  06-02
Minerva Neurosciences forms scientific advisory board for roluperidone program
Minerva Neurosciences enters equity distribution deal for up to $75 million ATM offering
Reuters  ·  05-28
Minerva Neurosciences enters equity distribution deal for up to $75 million ATM offering
Minerva Neurosciences - to Offer and Sell up to $75 Mln in Common Stock Through Leerink Partners - SEC Filing
THOMSON REUTERS  ·  05-28
Minerva Neurosciences - to Offer and Sell up to $75 Mln in Common Stock Through Leerink Partners - SEC Filing
Minerva Neurosciences publishes corporate presentation on roluperidone for schizophrenia negative symptoms
Reuters  ·  05-20
Minerva Neurosciences publishes corporate presentation on roluperidone for schizophrenia negative symptoms
Minerva Neurosciences CEO joins Jefferies Global Healthcare Conference fireside chat
Reuters  ·  05-19
Minerva Neurosciences CEO joins Jefferies Global Healthcare Conference fireside chat

Introduction

Company Name.
Minerva Neurosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Issue price:
--